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Pharmaceuticals that contain polycyclic
hydrocarbon scaffolds
Tegan P. Stockdale and Craig M. Williams*
Numerous variations on structural motifs exist within pharmaceutical compounds that have entered the
clinic. These variations have amounted over many decades based on years of drug development
associated with screening natural products and de novo synthetic systems. Caged (or bridged) bicyclic
structural elements offer a variety of diverse features, encompassing three-dimensional shape, and
assorted pharmacokinetic properties. This review highlights approximately 20 all carbon cage containing
pharmaceuticals, ranging in structure from bicyclo[2.2.1] through to adamantane, including some in the
top-selling pharmaceutical bracket. Although, a wide variety of human diseases, illnesses and conditions
are treated with drugs containing the bicyclic motif, a common feature is that many of these lipophilic
systems display CNS and/or neurological activity. In addition, to an extensive overview of the history and
biology associated with each drug, a survey of synthetic methods used to construct these entities is
presented. An analysis section compares natural products to synthetics in drug discovery, and entertains
the classical caged hydrocarbon systems potentially missing from the clinic. Lastly, this unprecedented
review is highly pertinent at a time when big pharma is desperately trying to escape flatland drugs.
1. Introduction
Many different structural motifs exist within pharmaceutical
compounds, which arise from decades of screening and evaluating
natural products1 and synthetic entities.2,3 A structure may be as
simple as the antibacterial agent acetic acid or as complex as a
chemotherapeutic natural product, such as paclitaxel (1) (Fig. 1).
That considered, the structure and functional groups incorporated
into a drug determine not only molecular recognition at the
target site, but also broader pharmacological properties, such as
membrane permeability, selectivity and susceptibility to meta-
bolic processes [i.e. absorption, distribution, metabolism, and
excretion (ADME)]. This premise alone has been the topic of
many wide ranging review articles in drug discovery.4–8 Reviews
targeting specific functional groups and structural motifs within
drugs and drug discovery have also appeared;9,10 however, a
survey covering approved pharmaceutical compounds incor-
porating polycyclic hydrocarbon scaffolds seems not to have
been undertaken. Polycyclic hydrocarbon, caged bicyclic (or
bridged bicyclic) scaffolds or motifs are simply defined as an
atomic bridge appended across an underlying ring of atoms
connected at bridgeheads (see extracted systems 2 and 4 in
Fig. 1). Such systems offer a variety of diverse structures,
encompassing three-dimensional shape and assorted pharmaco-
kinetic properties, often attributed to their hydrocarbon nature. They can differ substantially in size, and the identity of the
atoms that compose the cage skeleton, which is a substantial
sideways shift away from planar systems.11 These features have
facilitated a wide spectrumof approved pharmaceutical applications
Fig. 1 Paclitaxel (1) and buprenorphine (3) and their corresponding polycyclic
hydrocarbon core structural elements 2 and 4.
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ranging from smoking cessation to antitumour agents, some of
which are in the top-selling pharmaceutical bracket, e.g. buprenor-
phine (3) (Fig. 1).
Given the importance, and future inspiration, members of
this class offer, a review of the literature up to January 2014 was
performed. Selected databases were systematically searched to
identify pharmaceutical compounds incorporating polycyclic
hydrocarbon structures (all carbon atoms only) and to gather
information regarding their approval status and current appli-
cations: ‘‘Drugs@FDA’’ (Approved Drug Products) and the
‘‘DrugBank’’. Further searching, using PubMed and SciFinder,
was conducted for each identified compound in order to
compile comprehensive information regarding discovery,
synthesis, indications, pharmacology, mechanism of action
and areas of continuing research.
Approximately 20 all carbon systems were identified and these
are discussed below according to their polycyclic classification.
Lastly, some drugs discussed herein have been removed from the
market place, but are still under investigation for the treatment of
new conditions so they have been included herein.
2. Bicyclo[2.2.1]
2.1. Biperiden
Biperiden (5) is a weak peripheral anticholinergic agent used to
reduce symptoms of Parkinson’s disease (PD).12 Traditionally,
natural product anticholinergic agents, such as atropine (6) and
hyoscine (7), were used in PD symptom relief.13 However,
synthetic drugs were later developed in an attempt to lessen
side effects. Klavehn developed racemic biperiden in 1953 and
studied the activity of the molecule with Hass.14 The molecule
received patent protection in 1957,15 and was approved by the
FDA in 1959. It was marketed as Akinetont (Knoll and Abbvie)
(Fig. 2).
PD symptoms are thought to be at least partly attributable to
an imbalance in the corpus striatum caused by excessive
excitatory cholinergic activity over lesser inhibitory dopaminergic
system activity.16 Biperiden acts as a competitive antagonist of
cholinergic muscarinic receptor M1 in the central and peripheral
nervous systems and confers antisecretory, antispasmodic and
mydriatic effects.13,16,17 Blocking acetylcholine, and thereby
reducing cholinergic receptor activation, is thought to address
the dopaminergic–cholinergic imbalance. Due to commonality in
mechanism of action, all cholinergic drugs, including biperiden,
have similar adverse effects, including excitation, defective near
Fig. 2 Anticholinergic agents biperiden (5), atropine (6) and hyoscine (7)
used for treatment of Parkinson’s symptoms.
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vision, drowsiness and confusion, as well as effects such as con-
stipation and dry mouth associated with reduced secretion.12,13,16
Numerous PD drugs are now available, including amantadine
(100) (discussed below, Scheme 17);16 the strongest and most
widely used of these is levodopa.13 Biperiden may also be used
in moderate PD as a synergistic adjunct to levodopa and in cases
where levodopa is ineffective or not recommended.18
Biperiden is also used to relieve extrapyramidal disorders
secondary to neuroleptic drug administration.13,19,20 However, in
light of a recent study showing improved cognitive function and
quality of life following careful discontinuation of biperiden in
schizophrenic patients receiving second generation antipsy-
chotics, cessation of routine biperiden co-administration with
second generation antipsychotics was recommended.21 Recent
research has also indicated that biperiden affects appetitive
behaviour and pre-attentive auditory processing.22,23 It was sug-
gested that biperiden may have a role in addressing cocaine
dependence; however, further studies are required. Although
levodopa is now the PD symptom relief drug of choice, biperiden
retains a role in mild and moderate cases. Research on the
neurological effects of this drug still continues.24
Synthesis of biperiden (5) is relatively simple and a number
of different procedures exist.15,25,26 A more recent method
described by Kastner,27 starts with a Diels–Alder reaction
involving methyl vinyl ketone (8) and cyclopentadiene, which
affords the norbornene adduct (9), as a mixture of exo- and
endo-isomers. Isomerisation of 9 with methoxide gives predo-
minantly the exo-isomer (10), which is subjected to a Mannich
reaction with paraformaldehyde and piperidine to give ketone
11. Biperiden was then obtained as a racemate from exposure
of ketone 11 to phenyl magnesium bromide (Scheme 1).
2.2. Cyclothiazide
Cyclothiazide (12) is a member of the pharmaceutically active
benzothiazides, which are reasonably potent, orally effective,
diuretics.28 This class of drug, used to treat heart failure and
hypertension, was developed following a report by Schwartz in
1949, that sulfanilamide (13) produced a natriuretic effect in
congestive heart failure patients.28 Cyclothiazide was approved,
as a new diuretic antihypertensive in 1963, and marketed as
Anhydront by Lilly.
Thiazide diuretics act by interfering with the sodium and
chloride ion reabsorption in the distal cortical diluting region
of the renal tubule.29 Consequently, cyclothiazide decreases the
glomerular filtration rate.30 Unfortunately, however, this
mechanism of action also gives rise to side effects, such as
hyperglycaemia, hypokalaemia and hyperuricaemia.31 Lower
potency, relative to other diuretics, and a flattened dose–response
relationship render thiazides inappropriate for cases of severe
renal insufficiency.32 Although also used in Europe and Japan,
cyclothiazide has now been discontinued in the United States.
Despite this, further studies into the activity of cyclothiazide have
shown that it is a positive allosteric modulator of ionotropic
a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA,
14) glutamate receptors, blocking the desensitisation of these
receptors.33–36 It is no surprise then that this drug acts as a
negative allosteric modulator of the GABAA receptor.
37,38 For these
reasons, cyclothiazide may have relevance in the treatment of
depression.39
Cyclothiazide (12) was first synthesised in 1961 from the
condensation of norbornenal (15) and 6-amino-4-chlorobenzene-
l,3-disulfonamide (16), which is obtained from m-chloroaniline
(17), in 46% overall yield (Scheme 2).40–44 Information about the
stereochemical consistency of this drug is very limited. A report by
Gal45 determined, using a range of modern analytical techniques,
that, of the eight possible stereochemical isomers (i.e. four
racemates), all are present in the marketed drug. It was also
found that the norbornene endo configuration predominates
over the exo racemates, in addition to small but significant
differences in isomer distribution between different batches of
produced material.
2.3. Fencamfamine
Fencamfamine (18) is an anorectic psychostimulant developed
by Merck in the late 1950s.46,47 It was released as an appetite
suppressant, in countries such as Brazil, in the early 1960s.48
Scheme 1 Synthesis of biperiden (5). Scheme 2 Synthesis of cyclothiazide (12).
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However, the amphetamine-like stimulant properties of this
drug also led to recreational use.48–50 In the United States,
fencamfamine has been used illicitly as a cocaine substitute
and is now listed as a Schedule IV controlled substance.51,52
Pharmacologically, fencamfamine is a CNS stimulant that
increases locomotion and enhances alertness and mood.48,53–55
It acts by inhibiting the dopamine and norepinephrine reuptake
by the presynaptic neuron.53,55–57 Although fencamfamine dis-
plays amphetamine-like effects,57,58 it is viewed as a safer entity
than amphetamine, because it does not inhibit monoamine
oxidases.56 The addictive nature of fencamfamine has been
evidenced by conditioning place preference studies in rats, where
repeat administration was shown to have a reinforcing effect.59,60
The stimulant properties of fencamfamine were later optimised to
create the designer drug camfetamine (19). Although 19 is a more
potent stimulant than fencamfamine, it has a less favourable
safety profile with more adverse side-effects.61
The synthesis of fencamfamine (18) is relatively straight-
forward. A Diels–Alder reaction between cyclopentadiene and
b-nitrostyrene (20), first reported in 1939,62–64 gives rise to the
core structure (i.e. 21). The nitro group and carbon–carbon
double bond can be reduced separately, with iron filings in
acid, and hydrogen with catalytic platinum respectively, or in a
single step with hydrogen and a RANEYs-nickel catalyst (see
22). Subsequent N-ethylation gives fencamfamine in an overall
yield of 13–29%.62–64 The original synthetic procedure,
however, was recently optimised by Novakov et al. to increase
product yield in the hydrogenation and alkylation stages, while
maintaining product purity.65 Following the Diels–Alder reaction,
the core (i.e. 21) was directly reduced, with a nickel–aluminium
alloy, in the presence aqueous sodium hydroxide in tetrahydro-
furan to give 22. The hydrogenation was accelerated using this
protocol because nickel–aluminium and aqueous alkali react to
give molecular hydrogen. N-Alkylation was achieved by boiling
the amine in excess absolute alcohol with catalytic nickel metal,
giving fencamfamine (18) in an overall yield of 51–54%
(Scheme 3). Fencamfamine is administered as a dual racemic
mixture consisting of endo-N-ethyl/exo-phenyl and exo-N-ethyl/
endo-phenyl enantiomeric pairs in an approximate ratio of 9 : 1.65
2.4. Lurasidone
Lurasidone (23) is an atypical antipsychotic drug (APD) used to
treat schizophrenia and, more recently, bipolar I depression.66–69
It was designed and developed by Dainippon Sumitomo in Japan.
Lurasidone is marketed as Latudat (Sunovion Pharms Inc.) and
was approved by the FDA as a new molecular entity for schizo-
phrenia treatment in 2010 and approved for treatment of bipolar
I depression in June 2013. It differs from traditional APDs, and
other related APDs, having a more favourable safety and toler-
ability profile while maintaining similar efficacy.70 The disadvan-
tages of other related APDs, include weight gain, hyperlipidemia,
and glucose impairment. In contrast, lurasidone is neutral or
minimally adverse in these areas.67,71 It acts as a full antagonist at
the dopamine 2 (D2) and serotonin 2A (5-HT2A) receptor sites,
72–74
with the highest binding affinity to the 5-HT7 receptor,
72 and
partial agonist activity at the 5-HT1A receptor. The therapeutic
and safety differences are thought to be attributable to receptor
affinity differences, especially at the 5-HT7 receptor inter-
action.66,75–77 Weak affinity for norepinephrine a2C and
5-HT2C receptors, and negligible affinity for muscarinic receptors
and the histamine H1 receptor, has been suggested to be
responsible for minimal hypotension, sedation, weight gain,
hyperlipidemia and glucose metabolism impairment during
treatment.67,71
In bipolar I depression treatment, lurasidone has been shown
to be effective as a monotherapy,78 and is also an adjunctive
therapy with mood stabilisers.67,79 Bipolar depression has been
linked with high rates of metabolic syndrome and a significant
increase in the risk of cardiovascular disease,72,80,81 and there-
fore, the favourable metabolic profile of lurasidone will allow
treatment, while minimising cardiometabolic risk.
This drug can be described as a benzoisothiazole or an
azaspirone derivative.82–84 Originally, commercial synthesis
proceeded with construction of a disulfonate (24), by bis-
mesylation of 1,4-diol (25),79 which gave spirocyclic tetralkyl-
ammonium salt (26) when reacted with the piperazine
benzothiazole (27). The lurasidone (23) synthesis was com-
pleted via reaction of the [2.2.1]-bicyclosuccinimide (28) with
the spirocyclic tetralkylammonium salt 26 (Scheme 4).82–84 An
issue with this approach is that the benzoisothiazole, and
its intermediates are strong dermal, ocular, and nasal irritants,
requiring particular containment and cautious handling. Further-
more, the synthesis utilises other hazardous compounds/
reagents, and requires expensive separation processes to be
undertaken. Therefore, a number of newer asymmetric, scalable
and more commercially viable processes were explored, for
example, adding the trans-1,2-disubstituted cyclohexane (29)
to the [2.2.1]-bicyclo-succinimide (28), followed by sequential
piperazine formation (Scheme 4).85
Scheme 3 Synthesis of fencamfamine (18).
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2.5. Mecamylamine
Mecamylamine (30) is a nicotinic acetylcholine receptor
(nAChR) antagonist that was originally introduced to treat
hypertension.86 It was marketed as Inversinet (Targaceptt)
and approved by the FDA, as a new molecular entity in 1956.
It is rapidly, and almost quantitatively, absorbed through
the gastrointestinal tract and is, therefore, orally available,87
which was considered an advantage over existing poorly orally
available tertiary amines at the time.86 Furthermore, it had an
extended duration of action as a non-specific ganglionic
blocker.88 At therapeutic levels, this lack of specificity affected
the sympathetic and parasympathetic nervous system, giving
rise to a number of adverse side effects, including dry mouth
and constipation.88–90 Consequently, therapeutic use has been
discontinued, except in cases of severe hypertension, in favour
of more specific antihypertensives affecting only the sympa-
thetic nervous system.90 However, it has been shown that the
central effects of mecamylamine are observable at a dose three
times lower than that used to treat hypertension.91 This lower
dosage avoids or minimises the severity of side effects, allowing
for mecamylamine to potentially be used to treat conditions,
such as addiction and depression (e.g. smoking cessation91),
in which the nAChRs have been indicated to play a key role.92
Although promising use avenues have recently opened, at
this stage, no other therapeutic usage has been approved for
mecamylamine.93
The synthesis of mecamylamine (30) was described by Merck
researchers in 1956.94 The racemic synthesis commenced by
reacting racemic camphene (31) with hydrogen cyanide, under
strongly acidic conditions to form 3-formylamido-2,2,3-trimethyl-
norcamphane (32). Reduction with lithium aluminium hydride
gave mecamylamine (30). Enantiomerically pure mecamylamine
can be obtained by resolving racemic mecamylamine, using
D-camphorsulfonic acid in acetone (Scheme 5), or can be
synthesized directly from D-camphene.95
Structure–activity relationship (SAR) studies indicated that
alkylating the amine increased activity, but activity decreased as
the size of the alkyl substituent was increased.87 Thus, a methyl
group was optimal. Critical steric hindrance of the amine group
is essential for biological activity. In addition, the exo form is also
optimal as it was shown that maximal hindrance in the endo
form, with the amine resting within the cage, decreases activity.87
3. Bicyclo[2.2.2]
3.1. Maprotiline
The tetracyclic second generation antidepressant maprotiline
(33), is used to treat major depressive disorders and alleviate
associated anxiety.96 It was first synthesised in the 1960s and
was marketed in a number of countries, including England, in
the 1970s.97 However, it was not until 1980 that maprotiline
was approved by the FDA as a new molecular entity for the US,
marketed as Ludiomilt (Novartis).
Maprotiline is classified as a noradrenaline reuptake inhibitor.98
It is a strong inhibitor of noradrenaline reuptake in both neuronal
and peripheral tissues and a strong neuronal norepinephrine
reuptake inhibitor.99 This activity is thought to be attributable to
the secondary amine functionality.100 The sedative properties of
maprotiline are thought to be ascribable to strong antihistaminic
action. The absence of monoamine oxidase inhibition and weak
anticholinergic activity improves the safety profile of maprotiline
compared to some other antidepressants.101,102 The ethylene bridge
is the distinguishing feature from standard tricyclic antidepressant
molecules, which could be the reason for the above feature.98
Overall, maprotiline appears to have a similar, or even greater,
incidence rate of adverse events compared to standard tricyclic
antidepressants.103 Given that tricyclic antidepressants have the
highest potential overdose toxicity101,102 and that, despite structural
and biochemical differences, maprotiline has a similar pharmaco-
logical profile to tricyclic antidepressants, it is unsurprising that
selective serotonin reuptake inhibitors are the antidepressants of
choice.104,105 However, a recent study focussing on the potent
selective antiproliferative effects of maprotiline against Burkitt’s
lymphoma, and themechanisms ofmaprotiline induced apoptosis,
suggests that maprotiline may have a continued use in cancer
treatment.106,107
Scheme 4 Synthesis of lurasidone (23).
Scheme 5 Resolution of mecamylamine (30).
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The synthesis of this drug commences with the installation
of the eventual bridgehead substitution. This was achieved by
deprotonation of anthrone (34), and subsequent reaction with
acrylonitrile followed by hydrolysis with aqueous hydrochloric
acid, affording acid 35. Reduction of the keto function with zinc
gave the anthracene 36, which was poised to undergo reaction
with ethylene giving the bicyclo[2.2.2]octane system (i.e. 37).
Acid chloride formation, and direct conversion to amide 38,
facilitated access to maprotiline (33) after treatment with
lithium aluminium hydride (Scheme 6).97
3.2. Buprenorphine
Buprenorphine (3) is a semi-synthetic derivative of the opioid
alkaloid thebaine (39) and is used for moderate to severe pain,
pre-operative analgesia and treatment of opioid dependence.108,109
In light of the dependence issues with opium together with
dependence and adverse side effects of morphine, a detailed
campaign was undertaken in order to identify the factors respon-
sible for analgesic activity and those responsible for addiction
liability.109 In 1966, buprenorphine was identified, as a more
potent and longer lasting analgesic than morphine, with lower
dependence potential and favourable tolerability profile.109,110
It was initially developed as a non-addictive analgesic. It was
marketed as Buprenext (Reckitt Benckskiser), receiving FDA
approval as a new molecular entity in 1981.
Relatively low level doses are needed to achieve analgesia,
however, at higher doses buprenorphine, commonly in combi-
nation with naloxone (40), can be used as an addiction thera-
peutic.108 The potential of buprenorphine as an addiction
therapeutic was first announced in 1978.111,112 It is most
popularly marketed as Suboxonet (Reckitt Benckskiser),
a buprenorphine hydrochloride and naloxone hydrochloride
mix, which is used as an opioid agonist/antagonist to treat
opioid dependence. Suboxonet placed within the top 200
brand name drugs by US retail sales from 2006–2012, within
the top 200 worldwide sales in 2008 and 2009, and in the top
200 drugs by US prescriptions in 2010 to 2012. Further applica-
tions include intravenous, sublingual, implants and transdermal
patches.108,109,113 Buprenorphine was identified as a full agonist
at the ORL-1 receptor with an IC50 value of 8.4 nM.
114
Buprenorphine can actually be classified as a thevinol and
an orvinol, as it can be derived from both thebaine and
orvipavine (41). Buprenorphine (3) was first synthesised
by Bentley, in an eight-step process from thebaine (39).115
However, this synthetic process required high temperature
and pressure conditions and involved N-demethylation with
cyanogen bromide and phenolic O-demethylation with potassium
hydroxide in digol, both of which were difficult steps. When
orvipavine (41) was used as the starting material by Hudlicky
et al., in a six-step process, no O-demethylation was necessary and
a thiolate could be used for the N-demethylation of the quaternary
salt, thereby avoiding the use of cyanogen bromide.116 Whereas,
starting with thebaine Hudlicky reduced the process to six steps,
with an improved yield of 66% for the final three steps.117 The
shortened approach employs an advanced Diels–Alder inter-
mediate (42), which undergoes a demethylation/acetylation
sequence with cyclopropanecarboxylic acid anhydride mediated
by palladium acetate in air to give the N-acetamide (43).
Reduction and O-aryl demethylation afforded buprenorphine
(3) as the final product (Scheme 7).
Scheme 6 Synthesis of maprotiline (33) (not all yields reported97).
Scheme 7 Synthesis of buprenorphine (3).
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4. Bicyclo[4.4.1]
4.1. Ingenol mebutate
Ingenol mebutate (44) (ingenol 3-angelate) (Fig. 3), was
approved by the FDA in January 2012, as a new molecular
entity, marketed under the name Picatot (LEO Pharma) as a
topical application for treatment of actinic keratosis (premalignant
condition of thick, scaly, or crusty patches of skin). It is a natural
product metabolite found in a number of members of the
Eurphorbia family,118 first described in 1980 as a component of
E. paralias.119 Additional isolation sources have been reported
from E. antiquorum, E. helioscopia and E. virgate,120,121 but is most
well-known as a component of E. peplus.122,123
Originally used in traditional medicine to treat the precancerous
skin condition actinic keratosis and basal cell carcinomas,124,125
evaluation to determine whether there was a realistic pharmaco-
logical basis for traditional treatments, began in Australia in
2004.126 Tumouricidal activity was demonstrated against a number
of cell lines, including resistant cell lines. A 100% cure rate was
shown for three day topical application in mouse models of mouse
and human skin cancer lines.127 Further phase II and III human
trials evidenced the efficacy and safety for topical treatment of
actinic ketatosis.128 Preclinical and clinical study data were
employed to elucidate the mechanism of action of ingenol
mebutate.124,125 The initial cell line studies indicated that,
upon application cancerous cells were much more sensitive
to rapid mitochondrial disruption and cell death by primary
necrosis than normal cells.126 Ingenol mebutate inhibits protein
kinase C (PKC) a and activates PKCd in cancerous cells, thereby
inducing apoptosis with considerable potency.129–132 However, in
T cells, PKCy is activated creating a strong survival signal.133
A differentiating feature between cancerous and noncancerous
cells is that, while PKCd is expressed widely, PKCy is only highly
expressed in T cells and myocytes.134 Thus, in contrast to other
chemotherapeutic agents, which decrease immune function,
ingenol mebutate may in fact stimulate the immune system
while inducing cancerous cell death. In 2011, Rosen et al. con-
cluded that ingenol mebutate acts through a dual mechanism of
action causing both rapid lesion necrosis and specific neutrophil-
mediated, antibody-dependent cellular cytotoxicity, which is
crucial in precluding relapse.125 In human studies, a three day,
0.015% gel treatment course for facial areas and a two day, 0.05%
gel treatment course for trunk and extremities proved to be most
safe and efficacious.135 Although the majority of participants had
mild-moderate skin reactions,136 this is to be expected, given that
cell death is being induced in cancerous cells. Generally adverse
events were only of mild-moderate severity and included pain,
pruritus and irritation.136
The drug has also completed phase II clinical trials for basal
cell carcinoma treatment.128 Unfortunately, rapid degradation
through ester migration and hydrolysis result in poor pharmaco-
dynamics properties that would not be easily addressed by
available synthetic modifications.122 Thus, the broader applica-
tion of ingenol mebutate in treatment of cancerous conditions is
currently limited.
Semi-synthesis from the commercially available natural
product ingenol (45), extracted from E. lathyris seeds,137 has
been explored as an avenue to obtain commercially relevant
amounts of ingenol mebutate.138 However, only 275 mg of
ingenol (45) could be extracted per kg of seeds and further
synthesis was still required.137 In 2013, a new extraction
process was patented claiming an extraction of 750 mg of
ingenol (45) per kg of seeds.139 Still, the process was costly
and possibly not environmentally sustainable. Attempts to
develop a total synthesis for this diterpene class commenced
in the 1980s and it was recognised that development of a
synthetic approach for ingenol (45)140 would allow synthesis
of multiple analogues, including ingenol mebutate. However, it
has only been recently, with the publication by Baran et al. of a
14 step synthesis of (+)-ingenol (45) from (+)-3-carene (46), that
fully synthetic commercial production has become a potentially
viable option.141,142 Although three total syntheses, and one
formal synthesis, of ingenol (45) have been published, these
approaches involved 35–47 steps, rendering them commercially
non-viable, especially as ingenol (45) is not the desired final
product.143–145 Baran et al.141,142 applied a retrosynthetic
approach employing two main phases: a cyclase phase, to form
the tigliane carbon skeleton and an oxidase phase, to achieve
rearrangement to the ingenane skeleton, and thus create the
necessary hydroxyl functionalities. In determining the best
method to obtain the in-out bridged core of the molecule,
inspiration was sought from the biosynthetic pathway of ingenane
terpenoids.146 A 1,2-pinacol rearrangement was necessary to
obtain ingenane from tigliane.147 Despite the thermodynamic
challenge of a favourable reverse reaction, the vinylogous
pinacol rearrangement was considered to be a crucial simplifying
synthetic step.
The cyclase phase (Scheme 8) to obtain the tigliane core was
seen as an endpoint from which analogues such as ingenol
mebutate (44) may be obtained. The alkene functionality on carene
(46) was exploited to install chlorine as a leaving group (i.e. 47),
and ozonolysis was used to create chloroketone 48. This facilitated
alpha methylation followed by an aldol reaction to install C-11
(i.e. 49) using allenal 50. An ethynyl unit was installed to drive a
Pauson–Khand cyclisation (i.e. 51),148 which would create fused
rings A and B, after the hydroxyl functionalities were protected
(i.e. 52). Methyl magnesium bromide was then utilised to install
the C-2 methyl group (53), providing the cyclase phase endpoint.Fig. 3 The structure of ingenol mebutate (44).
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The oxidase phase (Scheme 9) began with the dihydroxyla-
tion of the B ring alkene with osmium tetroxide (i.e. 54). The
hydroxyl functionalities were then protected as carbonate 55,
before the key vinylogous pinacol reaction was undertaken
providing the ingenol framework (56). Careful manipulation
of reaction temperature was needed as it had previously been
reported that thermodynamic factors favour the reverse reaction.149
Allylic oxidation was used to install the C-3 hydroxyl (i.e. 57).
Addition of Martin’s sulfurane150 and base hydrolysis caused
elimination of C-6 and global deprotection. Creation of hydroxyl
functionality was challenging due to steric hindrance. However,
Shibuya’s conditions151 were successfully employed to undertake
allylic oxidation of the crowded bicyclic olefin and obtain the
final product (45) in 1.2% overall yield. Although this is a low
yield, it is favourably comparable to the 0.028% w/w and more
recent 0.075% w/w obtained by extraction from E. lathyris
seeds137,139 and the 0.0011% w/w of ingenol mebutate (44)
obtained from isolation from E. peplus.123
5. Bicyclo[5.3.1]
5.1. Paclitaxel
The taxanes have become the major treatment choice in a
broad range of solid cancers, including breast, prostate, ovary,
lung, head and neck tumours.152–154 The class of chemothera-
peutic taxanes is composed of paclitaxel (1) (Taxolt, Bristol-
Meyer Squibb), docetaxel (58) (Taxoteret, Sanofi-Aventis) and
cabazitaxel (59) (Jevtanat, Sanofi-Aventis) (Fig. 4). These drugs
all act via the same broad mechanism of action to induce
cell death through binding to b tubulin and promotion of
microtubulin polymer assembly.155 However, the binding also
stabilises microtubules, preventing the lengthening and short-
ening of the microtubules that normally allows chromosome
movement during cell division. Therefore, the taxanes act by
preventing cell division, effectively arresting the cell cycle and
leading to cell apoptosis. Issues with resistance have arisen
with both paclitaxel and docetaxel, especially in the realm of
treating metastatic castration-resistant prostate cancer (mCRPC).
However, these drugs continue to improve the life expectancy in
a range of cancerous conditions, while exhibiting an acceptable
therapeutic safety profile. Docetaxel based chemotherapy
remains a cornerstone in the treatment of mCRPC and cabazi-
taxel has become the standard second-line chemotherapy.
Cabazitaxel based treatments have also emerged as follow-on
treatments to docetaxel based treatment.156,157
Scheme 8 Cyclase phase to obtain the tigliane core in the synthesis of
ingenol mebutate (44).
Scheme 9 Key stages in the final synthesis of ingenol (45).
Fig. 4 Chemotherapeutic taxanes: paclitaxel (1), docetaxel (58) and caba-
zitaxel (59).
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Paclitaxel is the original pharmaceutical taxane. It is a highly
complex natural product that was isolated from Pacific yew
(Taxus brevifolia) bark in 1967.158–162 In 1992, the FDA approved
paclitaxel as a new molecular entity. Paclitaxel has been found
to be effective in a number of different cancers, including
breast cancer,163–166 non-small cell lung cancer (NSCLC),167,168
ovarian cancer,169 prostate cancer,170 AIDS-associated Kaposi’s
sarcoma171 and, possibly, pancreatic cancer.172,173 Paclitaxel
ranked in the top 200 US brand name drugs in 2011 and
2012, when marketed as Abraxonet (Celgenet), for treatment
of breast cancer, NSCLC and pancreatic cancer. The nanoparticle
formulation of this drug promotes binding with albumin,
decreasing hypersensitivity and increasing cellular uptake.172,173
Paclitaxel directly affects mitotic spindle function during G2
and M phases, causing cell cycle arrest and cell death.174 It also
induces bcl-2 phosphorylation, leading to apoptotic cell death.175
Themajor limitation, reducing paclitaxel efficacy, is the emergence
of multidrug resistance transporters.153,174 These transporters,
particularly P-glycoprotein (P-gp; ABCB1), act as efflux pumps,
expelling the drug from cancerous cells, preventing it from reach-
ing pharmaceutically relevant concentrations within cells.174 There
are also adverse reactions associated with paclitaxel treatment,
namely haematological events (neutropenia, thrombocytopenia,
anaemia), nausea and diarrhoea.
Although the structure was published in 1971,158–162 due to
the size and complexity of the molecule, it was over 20 years
later, in 1994, that two total syntheses were reported basically at
the same time by Nicolaou et al.176,177 and Holton et al.178,179
Even though paclitaxel had been approved as an anticancer
agent at this stage, the low yield and detrimental environmental
consequences of natural harvesting acted as a strong incentive to
develop a synthetic, semisynthetic or bioengineering route
to obtain relevant quantities of paclitaxel. In the view that
taxane synthesis has been previously reviewed on a number
of occasions159–161 only the Nicolaou and Holton syntheses are
presented below in brief.
The Nicolaou group took a retrosynthetic approach involving a
Shapiro reaction,180,181 which joined the two fragments 60 and 61
to create the precursors for rings A and C. McMurry coupling was
then employed to cyclise the system and obtain the ABC ring
skeleton (i.e. transformation 62 to 63). The subsequent installa-
tion of the oxetane ring was to be followed by creation of the B and
C ring peripheral functionalities and C-13 oxygenation, before
final attachment of the side chain by esterification with Ojima’s
b-lactam182 gave the side chain, which was then deprotected to
give the final paclitaxel product. Despite employing a convergent
synthesis approach, commencing from two previously reported
intermediates,183–185 the sequence required 27 steps (Scheme 10).
The Holton group synthesis constructed the core of paclitaxel
(i.e. 64) from the epoxidation, and subsequent fragmentation, of
the alkene 65 derived from b-patchoulene. This Grob type
fragmentation was developed over a nine year period by the
Holton group and was put to good effect. The C and D rings were
then laboriously installed (i.e. traversing intermediates 66 and
67), with final deprotection and sidechain installation providing
the target (Scheme 10).
Both syntheses were milestone accomplishments, which
were long and intensive synthetic campaigns, yielding limited
amounts of material. Thus, neither route was feasible for the
production of paclitaxel on a commercial scale. However, semi-
synthesis reality emerged when it was discovered that the
English yew (T. baccata) contained significant amounts of the
natural products 10-deacetylbaccatin III (68) and baccatin III
(69) (Fig. 5).158–162 In later years problems in commercially
viable isolation of paclitaxel itself have been overcome by plant
cell culture technology.162
Scheme 10 Key steps in the synthesis of paclitaxel: Nicolaou route top
and Holton route bottom.
Fig. 5 Baccatin natural products 68 and 69 used in semi-synthesis of
paclitaxel (1).
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5.2. Docetaxel
Like other taxane drugs, docetaxel (58) is a semi-synthetic
taxane analogue that was derived from the parent structure,
paclitaxel (1), through examination of structure–activity rela-
tionships.186 It was first approved by the FDA in 1996 as a new
molecular entity for use in locally advanced or metastatic breast
cancer.163,164 It has also been approved for use, after initial
paclitaxel treatment, in ovarian cancer and NSCLC.187,188 Since
the TAX 327 trial189 and subsequent FDA approval, in 2004,
docetaxel has been the standard-of-care first-line-treatment for
mCRPC.190
Docetaxel is structurally different from paclitaxel in that C10
has a hydroxyl rather than an acetate ester, which increases the
hydrophilicity and solubility of the molecule. Also the phenyl-
propionate side chain has a t-butyl carbamate ester in place of
benzyl amide. As a result of these structural changes, docetaxel
has almost twice the binding affinity for b-tubulin.154 Conse-
quently, docetaxel affects a broader range of the cell cycle,
including S, G2 and M phases. It may be this broader range
span of activity that allows docetaxel to be active in paclitaxel
resistant cells. The disruption of centrosome organisation,
during S phase, results in incomplete mitosis. Furthermore, doce-
taxel need only be present at a hundredth of the concentration of
paclitaxel to exert the same extent of bcl-2 phosphorylation.175
In the specific case of mCRPC, studies indicate that docetaxel
impairs androgen receptor nuclear translocation and activity to
suppress tumour growth.191
Comparison studies between the two drugs (i.e. paclitaxel
and docetaxel) indicate that docetaxel experiences greater
cellular uptake and reduced efflux, resulting in longer retention
time in cells.153 Although docetaxel treatment does cause higher
dermatologic responses, fluid retention and pulmonary toxicity,192
it results in less neuropathy, myalgias and hypersensitity, without
reducing efficacy, when compared with paclitaxel.187,193 A major
cause for low activity and resistance to both these drugs (i.e. 1 and
58) is that both act as substrates for the multidrug resistant efflux
pumps, particularly P-gp.194,195
The synthesis of docetaxel (58) is achieved by further modi-
fying paclitaxel, for example, as demonstrated by Kingston.196
First the sidechain and C7 hydroxyls were protected as a
benzylcarbonate and TES groups respectively, and then reaction
with di-tert-butyl dicarbonate gave 70. Reaction with magnesium
methoxide and deprotection gave docetaxel (Scheme 11).
5.3. Cabazitaxel
Cabazitaxel (59) is a semi-synthetic chemotherapeutic that
makes up the last member of the pharmaceutical taxane family.
It was designed to be a poor P-gp substrate, such that it was less
susceptible to resistance attributable to multidrug efflux
pumps.197,198 The nature of cabazitaxel as a poor P-gp substrate
is thought to be the key explanation for the effect of this drug in
cases of docetaxel (58) resistance.197,198 Such a drug was
particularly desirable in light of the fact that there was pre-
viously no second-line chemotherapy treatment available for
docetaxel resistant cancer.199 After the successful phase III
TROPIC trial,156 cabaxitaxel was approved by the FDA in 2010
as a new molecular entity, and has become the standard-of-care
second-line mCRPC treatment drug.200–202
This drug differs from docetaxel in that two of the hydroxyl
groups are replaced with methoxy groups. It is this change that
is thought to account for the increased ability of cabazitaxel to
permeate the blood brain barrier.203 Like paclitaxel (1) and
docetaxel, cabazitaxel binds to b-tubulin.204 It acts in the G2
and M phases to arrest cell cycle, leading to cell death.
Although cabazitaxel increases survival time in docetaxel-
resistant patients, the incidence of adverse events, such as
Scheme 11 Synthesis of docetaxel (58) from paclitaxel (1).
Review Article Chem Soc Rev
Pu
bl
ish
ed
 o
n 
14
 Ju
ly
 2
01
5.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f Q
ue
en
sla
nd
 on
 24
/07
/20
15
 01
:48
:40
. 
View Article Online
This journal is©The Royal Society of Chemistry 2015 Chem. Soc. Rev.
allergic responses, neutropenia, diarrhoea and treatment-
related mortality, is increased.205 Currently a number of clinical
trials involving cabazitaxel are being undertaken to determine
optimal dosage, combinations and sequencing.200–202 Many
cell lines have been exposed to this drug with considerable
potency being observed.206
Zhang and Fang207 recently reported an optimized synthesis
of cabazitaxel starting from 10-deacetylbaccatin III (68)
(Scheme 12). Protection of the C-7 hydroxyl as a triethylsilyl
(TES) ether allowed selective methylation with sodium hydride
giving the TES intermediate, which was methylated with tri-
methyloxonium tetrafluoroborate (i.e. 71). Attachment of the
sidechain using the known protected b-lactam (72) followed by
deprotection afforded cabazitaxel (59) (Scheme 12).
5.4. Dezocine
Dezocine (73) (Dalgant, AstraZeneca) was approved by the FDA,
as a new molecular entity, in 1986. It has been used as an
analgesic for moderate-severe post-operative pain,208,209 renal
colic210 and severe cancer pain.211,212 A 2011 study concluded
that preoperative administration of low dosage dezocine
improved post-laparoscopic surgery pain and reduced requests
for pain relief. However, despite the generally favourable pharma-
ceutical profile of dezocine, the drug was discontinued by the FDA
in 2011.
It was identified, through SAR studies, as a compound
having analgesic properties comparable with morphine
(74),213,214 but also shares broad structural similarities with a
number of other mixed agonist–antagonist pharmaceutical
compounds, including butorphanol (75) and pentazocine (76)
(Fig. 6). Unlike traditional analgesic opioid receptor agonists,
dezocine is a synthetic mixed agonist–antagonist.215 Significant
limitations of pure opioid receptor agonists, such as morphine
(74), include associated respiratory depression, tolerance and
dependence liability. In contrast, mixed agonist–antagonists
display a ceiling of respiratory depression. The issue with mixed
agonist–antagonists, such as butorphanol (75) and pentazocine
(76), is that they display other serious adverse reactions, including
nausea, significant sedation and psychomimetic effects.216,217
Thus, there appeared to be a gap for an effective mixed agonist–
antagonist analgesic with a desirable safety profile.
Animal and human clinical studies found dezocine to be
at least as effective as morphine,211,218–222 nalbuphine,218
pethidine223,224 and butorphanol,216,225–227 in therapeutically
comparable dosages, as an analgesic for moderate to severe
pain.227 Dezocine displays the ceiling effect for respiratory
depression at a comparably high level of analgesia and was
found to work well in combination with morphine.215 Perhaps
most importantly, adverse effects, such as sedation and nausea,
were found to be mild, dose-dependent and transient. Studies
concluded that dezocine is generally tolerated at least as well as
morphine, pethidine, butorphanol and nalbuphine, and was
consistently preferred by patients’ and physcians’.215,218 Due
to the agonist–antagonist nature of dezocine the risk of depen-
dence was reduced.228 Like morphine, the effects of dezocine
are fully reversible through naloxone administration.221
Furthermore, whereas tolerance and toxicity upon extended
administration of other agonist–antagonists, such as butorphanol,
led to discontinuation of treatment, extended dezocine adminis-
tration did not cause similar tolerance or toxicity.216
Dezocine (73) is synthesised from 1-methyl-7-methoxy-2-
tetralone (79),213,214 via alkylation with 1,5-dibromopentane in
the presence of potassium t-butoxide (i.e. 80). Subsequent
treatment with sodium hydride (NaH) drives cyclisation, com-
pleting the bridge junction (i.e. 81). Reaction with hydroxy-
amine affords oxime 82, which is then reduced, over a RANEYs
Scheme 12 Synthesis of cabazitaxel (59) from 10-deacetylbaccatin III (68).
Fig. 6 Mixed agonist–antagonist analgesics: dezocine (73), morphine (74),
butorphanol (75), pentazocine (76), nalbuphine (77) and pethidine (78).
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nickel catalyst, to give the aminotetralin (83). Resolution of the
a and b amine epimers was achieved by fractional crystal-
lisation or chromatography. This was found to be improved
by treatment with D- and L-tartaric acid, and fractional crystal-
lisation.229 Treatment with HBr converts the phenyl methoxy
functionality to the desired hydroxyl functionality (Scheme 13).
5.5. Retapamulin
Retapamulin (84) is an antibiotic, used in ointment form
(1% 84) to treat skin infections, such as impetigo, largely caused
by Staphylococcus aureus and Streptococcus pyogenes.230–233 It is a
tricyclic diterpenoid derived from the natural product pleuro-
mutilin (85). The discovery of pleuromutilin (85), isolated from
the basidiomycete bacterial species Pleurotus mutilis (now known
as Clitopilus scyphoides) and Pleurotus passeckeranius, was reported
in 1951.234,235 Pleuromutilin was found to have modest anti-
bacterial activity against Gram-positive bacteria.234 However, due
to poor pharmacodynamic properties and toxicity, was unsuitable
for systematic use.236 SAR studies revealed that suphanyl-acetate
modifications at C-14 increased activity against Gram-positive
bacteria and mycoplasms.237 Indeed such modifications gave rise
to the veterinary compounds tiamulin (86) and valnemulin (87).238
Interestingly, retapamulin showed higher antimicrobial activity
than pleuromutilin,237,239 but it too had poor oral absorption
and rapid metabolism, leading to a short half-life, and rapid
excretion.238 Nevertheless, having been shown to have comparably
efficacious to fusidic acid (88) and oral cephalexin (89),240–242
retapamulin became the first new topical application antibiotic
within the last 20 years (Fig. 7).240
This drug has been shown to be well tolerated, with few
adverse side effects.240–242 This may be largely due to the fact
that it is topically, rather than systematically administered, and
has low systematic absorption. After successful clinical trials,
retapamulin ointment for treatment of impetigo (marketed as
Altabaxt by GlaxoSmithKline), was approved in 2007 by the
FDA as a new molecular entity. In the EU, where it is also
marketed as Altargot (GlaxoSmithKline) retapamulin was also
approved, for the short-term treatment of the following super-
ficial skin infections: impetigo and infected small lacerations,
abrasions, and sutured wounds.
Retamapulin, like other antibiotics, such as b-lactams and
quinolones, exerts its antibiotic activity by inhibiting protein
synthesis.243 However, the unique mechanism of action by
which this occurs avoids the occurrence of cross resistance,
experienced by antibiotics that have the same target as existing
antibiotics.230–233 Mutilins, such as retapamulin, inhibit the
initiation of protein synthesis by binding to a specific site on
the 50S subunit of the bacterial ribosome.243 By selective
binding, pleuromutilins inhibit peptidyl transfer, block P-site
interactions, and prevent the normal formation of active 50S
ribosomal subunits.243 Schild analysis indicates that the binding
of retapamulin is not competitive with P-site tRNA, suggesting
that there is an allosteric component to the inhibition of tRNA
binding.230–233 In addition to a different mechanism of action
than existing antibiotics, retapamulin has a low propensity to
resistance development.244 This is because retapamulin exhibits
a multistep resistance pathway for ribosomal protein L3, in which
the most resistant third-step mutants are also affected by growth
defects and frequently revert to more swiftly growing retapamulin
sensitive strain. As resistance to existing treatments, such as
topical fusidic acid, increases, retapamulin will become a more
attractive treatment option.244,245
It is no surprise that the complex structural features of
retapamulin are naturally-derived. This tricyclic diterpene con-
tains two caged bicyclic structures: a [5.3.1]bicyclo and a
[3.2.1]azabicyclo motif, which has been synthesised previously,
most recently by Procter et al.246 A brief overview of their
synthesis is presented below in Scheme 14. The synthesis began
Scheme 13 Synthesis of dezocine (73). Fig. 7 Tricyclic diterpenoids derived from the natural product pleuro-
mutilin (85) [retapamulin (84), tiamulin (86), valnemulin (87)], the topical
antibiotic fusidic acid (88), and cephalexin (89).
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with the chiral pool terpene, (+)-trans-carvone (90), which was
elaborated into the key intermediate dial (91) poised for a
samarian diiodide-mediated pinacol reaction affording the
bicyclic framework (92). Further manipulation of the peripheral
functionality and alcohol oxidation states, via intermediates 93
and 94, delivered the target [pleuromutilin (85)] with expe-
diency and efficiency (Scheme 14).
Retapamulin, however, is produced by a semi-synthetic
route using naturally occurring pleuromutlin, which is itself
biosynthesised.247 This commences with tosylation of pleuro-
mutilin with tosyl chloride, followed by reaction with thiourea
to give a thiourea ester. The thiourea ester is hydrolysed to the
thiol (95) and then used to substitute tropine mesylate (96) to
give retapamulin (84) (Scheme 15).
6. Tricyclo[3.3.1.13,7]
The adamantane class is composed solely of synthetic drugs,
covering seven drugs approved for a wide range of clinical
conditions. Current approved uses for pharmaceuticals within
the adamantane class of compounds range from Influenza A,
Herpes simplex and Acne vulgaris treatments, to Parkinsonism,
Alzheimer’s disease and type II diabetes mellitus. The common
feature of the adamantane class of compounds is a substituted
adamantyl system, tricyclo[3.3.1.13,7]decane (97) (Fig. 8).
Adamantane (97, R1 = R2 = R3 = H), was first isolated from
crude oil in 1933,248 and first synthesised in 1941.249 However,
it was not until the development of Schleyer’s adamantane
synthesis in 1957 that adamantane synthesis and derivative
research markedly increased.250 Schleyer’s synthesis proceeds
via Lewis-acid induced rearrangement of tetrahydodicyclo-
pentadiene (98). Once the cage is formed, the tertiary position
can then be brominated (i.e. 99)251 and substituted with the
desired functionality (Scheme 16). For the more structurally
complex members of the adamantane subgroup, syntheses
diverging from this general scheme have been developed.
Drugs in the adamantane class have desirable pharmaco-
dynamic properties attributable to the presence of the adamantyl
functionality. The hydrocarbon nature of the adamantane group
increases lipophilicity, allowing such molecules to move more
easily across biological membranes, as elegantly summarized by
Wanka and Schreiner.252 This is of crucial importance in the area
of central nervous system (CNS) drugs that need to travel across
the blood brain barrier to reach their target sites.253,254 Further-
more, this lipophilic moiety can be added to pharmaceutically
active compounds and known pharmacophors to improve phar-
macokinetic properties or to exploit a lipophilic pocket in the
target in order to increase selectivity.252,255–257 These favourable
properties have prompted studies investigating the potential for
use of adamantyl containing compounds in cancer and CNS
diseases, such as those involving the AMPA and KATP channels
Scheme 14 Synthesis of pleuromutilin (85) by Procter et al.
Scheme 15 Synthesis of retapamulin (84). Scheme 16 Formation and functionalisation of adamantane (97).
Fig. 8 The adamantyl system, tricyclo[3.3.1.13,7]decane (97).
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and the GABAergic system.252 That being said, for a number of
members of the adamantane family the mechanism of action and
mode of binding of the drugmolecule to its biological target has yet
to be fully elucidated. For other members of the class, the major
issue is resistance. Overall, however, it appears that the adamantane
class of compounds is a valuable and developing class of drugs.
6.1. Amantadine and rimantadine
Amantadine (100) is the first pharmaceutical derived from
the adamantane scaffold. Rimantadine (101), a derivative of
amantadine, also forms part of the adamantane family of
compounds. Amantadine and rimantadine are both antiviral
compounds that have been used to treat Influenza A.258 The
antiviral activity of amantadine was reported in 1963,259 with
Influenza A antiviral activity confirmed in tissue culture, chick
and mouse models.260,261 The FDA approved amantadine, as
a new molecular entity, for use in Asian flu, in 1966 and for
Influenza A in 1976. The drug has been marketed as Symmetrelt
(Endo Pharm) and Symadinet (Solvay).
It should be noted that amantadine was not a drug devel-
oped for a disease with a known mechanism, but rather was
identified as a hit in a random screen. Similarly, rimantadine
was a hit in further SAR screening, completed without prior
knowledge of the target.262,263 It is a racemic mixture, with
equipotent enantiomers, which is more potent than amanta-
dine.262 Rimantadine was approved by the FDA, as a new
molecular entity, for treatment of Influenza A, in 1993 and is
marketed as Flumadinet (Caracao).
Both these drugs are M2 ion channel blockers.
264 This conclu-
sion was reached only after extensive and wide-rangingmechanistic
studies.264–267 These studies commenced from sequence compar-
ison between wild type and resistant Influenza A strains, showing
that differences existed in the M2 protein transmembrane
sequence.268,269 More recent NMR and X-ray crystallography studies
indicate that, although there may be allosteric interaction sites,
amantadine and rimantadine bind inside the M2 ion channel,
blocking proton movement.270 This affects important pH balances
and pathways that control the uncoating of the viral particle,
thereby affecting the infectiveness of the virus.271 The consensus
from the most current structural studies strongly indicates that
binding consists of hydrophobic interactions between the adamantyl
group and the N-terminal channel gate, and water mediated inter-
actions with key residues.264 Studies of the mechanism of action of
amantadine and rimantadine have led to further elucidation of the
Influenza A viral replication process and also allowed for the design
of derived pharmaceutically active compounds that avoid inter-
actions that give rise to building resistance against amantadine
and rimantadine.264
The synthesis of amantadine is trivial, as derived from a number
of different strategies. Bromoadamantane (99) can be lithiated and
then reacted with chloroamine.272 Alternatively adamantane (97)
[or bromoadamantane (99)] can undergo a Ritter reaction, and then
be hydrolysed (Scheme 17).255–257 More recently, microwave-
assisted deacylation of unactivated amides using ammonium-
salt-accelerated transamidation has been used to transform
N-acetylamantadine (102) to amantadine (100) (Scheme 17).273
Rimantadine can be produced by a series of 1,2-anisotropic
rearrangements from 1-boraadamantane274 or by titanium(IV)
catalysed reductive amination of acetyladamantane (103).275
However, the initial synthesis by Stetter,276,277 which was
utilised by Aldrich262 to develop this drug, was conversion of
acetyladamantane (103) to the oxime (104) followed by
reduction with lithium aluminium hydride to rimantadine
(101) (Scheme 18).
A patient taking amantadine, who also suffered from
Parkinson’s disease (PD), reported experiencing relief in PD
symptoms.278 This led to successful clinical trials279 and con-
firmatory studies.280 In 1973, the FDA approved an additional
indication for use in treatment of PD symptoms. It is thought
that amantadine lessens PD symptoms, such as tremors and
dyskinesia, by increasing presynaptic terminal dopamine
release.281,282 In this way a further indication for amantadine
was serendipitously added.
6.2. Memantine
Memantine (105) was first patented by Merz, in 1973, as a PD
treatment.283 However, numerous studies, mentioned above,
indicated that amantadine was a much more effective PD
treatment. In a summary of early studies, Maj emphasised that
the major CNS effect of memantine was its influence on the
dopaminergic system.284 Yet, a clinical trial, in 1986, showed
no significant difference between memantine and placebo in
treatment of dementia.285 Further studies showed that memantine
is a non-competitive, voltage-dependent N-methyl-D-aspartate
(NMDA) receptor antagonist, with low-moderate affinity and
fast on/off kinetics.286
Memantine binds to the NMDA receptor only when the
receptor is opened by NMDA or an endogenous agonist,
such as glycine or glutamate.287 Although, not yet completely
Scheme 17 Microwave-assisted synthesis of amantadine (100).
Scheme 18 Synthesis of rimantidine (101).
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resolved, evidence elucidating the mechanism of action of
memantine is accumulating.288 The consensus emerging from
numerous studies is that memantine acts as a neuroprotective
compound by acting as a channel blocker, preventing over-
activation of NMDA receptors by high glutamate levels. This
avoids excessive Ca2+ influx into neurons and resultant excito-
toxicity.289 Overall, memantine appears to promote or preserve
synaptic plasticity and protect against cholinergic neuronal
degradation.
Due to these neuroprotective features of memantine, it is
used to treat the neurodegenerative symptoms of Alzheimer’s
disease (AD).290,291 In 2002, the European Medicines Agency
(EMA) approved memantine as an AD treatment. This was
followed by FDA approval of memantine as a new molecular
entity for treatment of AD in 2003. Memantine hydrochloride is
marketed as Namendat (Forest Labs) and quickly became a top
selling drug. From 2006 to 2012, in surveyed years, Namendat
was ranked in the top 200 US brand name drugs. It also ranked
in the top 200 drugs for worldwide sales, in 2008–2009, and US
prescriptions, in 2010–2012. Furthermore, memantine is the
only approved drug for treatment of moderate to severe AD and
has been shown to act synergistically with existing acetylcholi-
nesterase inhibitors.292 A number of mono- and combination-
therapy clinical trials have been undertaken, and the results
of key trials were recently evaluated.292 The comparative meta-
analysis paper found that memantine recipients displayed a
significant and consistent benefit in cognition, ability to under-
take daily living activities and overall assessment, compared
with placebo recipients. The authors concluded that memantine
appears to be a valuable pharmaceutical compound for treatment
of the neurodegenerative symptoms of AD.
The original synthesis of memantine (105), required as
a hypoglycaemic sulfonylurea intermediate, was reported by
Gerzon et al.,255–257 who applied Stetter’s procedure for the
synthesis of adamantylamine (100, amantadine) to 1,3-dimethyl-
adamantane (106).293 Gerzon reacted 1,3-dimethyladamantane
(106), obtained from methylcyclopentadiene dimer (107),293 with
excess bromine to give the bromide (108). Subsequent treatment
of the bromide (108) with acetonitrile and sulphuric afforded the
acetamide (109), which was hydrolysed with sodium hydroxide
to the primary amine (Scheme 19). More recently, however,
memantine has been prepared with excellent conversion from
1-formylamido-3,5-dimethyladamantane (110) in the presence of
sodium hydroxide in n-butanol (Scheme 19).294
6.3. Adapalene
Adapalene (111) (Fig. 9) is an anti-acne topical application
marketed as Differint (Galderma), and was approved by the
FDA in 1996 as a new molecular entity. It has enjoyed high
sales, ranking in the top 200 brand name drugs in US retail
sales in 2006, 2007, 2008 and in the top 200 brand names and
prescription sales in 2010. Adapalene is also marked in combi-
nation with benzoyl peroxide as Epiduot (Galderma). A number
of studies indicate that adapalene may be effective in other
cutaneous disorders, such as rosacea.295–297
It was identified in SAR studies as a mimic of vitamin A
(112), with the adamantyl group delivering the bulky hydro-
carbon unit and the aryl component providing the p compo-
nent.298,299 Vitamin A (112) is the original retinoid and binds to
retinoic acid receptor (RAR), retinoid X receptor (RXR) and
cytosolic retinoic acid binding protein (CRABP).300 Adapalene
binds selectively to RAR-b and RAR-g as an agonist. RAR-g
is thought to mediate the efficacy and irritation levels of
retinoids.301 The selectivity of adapalene decreases skin irrita-
tion suffered with previous retinoids and is a more effective
acne treatment.302,303 Additionally, increased stability, which is
likely due to the adamantyl functionality, overcomes previous
light degradation issues and allows adapalene to be used in
combination formulations.298,299,304
The synthesis of adapalene was first described by Shroot in
a 1986 patent298,299 and a later report by Charpentier.305 In
the original description adamantanol (113) was reacted with
4-bromophenol (114) giving the aromatic substitution product
116. The key step consisted of generating the organozinc
reagent (115) from the Grignard of 2-(1-adamantyl)-4-
bromoanisole (116) and reacting that with methyl-6-bromo-2-
napthenoate (117), mediated by nickel catalysis (Scheme 20).
The main issue with this approach was that the yield of
2-(1-adamantyl)-4-bromoanisole (116) was low, and the majority
appeared to undergo formal reduction before engaging with the
electrophile (117), resulting in an overall yield of 32%. Further-
more, the extraction and purification was highly laborious.
A recent paper reported successfully pursuing an optimised
Scheme 19 Synthesis of memantine (105).
Fig. 9 Adapalene (111) a mimic of vitamin A (112).
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Suzuki–Miyaura method,306 using boronic acid 118,307 which
gave an increased overall yield of 57%. Altered extraction and
purification conditions also improved production (Scheme 20).
6.4. Tromantadine
Tromantadine (119), like amantadine (100) and rimantadine
(101), was identified during SAR studies when screening for
antiviral activity.308 The drug displays antiviral activity against
Herpes simplex (HSV) and Herpes zoster.308 It has been approved
in South America, and some European and Asian countries,
for use in treating cold sores. It is marketed as Viru-Merzt
(Merz & Co.), as a topical application hydrogel. However,
tromantadine is not a first-line HSV treatment. The reason is
that comparative clinical trials did not show significant efficacy
differences,309,310 contact dermatitis has been reported to arise
in a small number of patients, with some studies reporting
incidences of less than one percent, while others suggest as
high as six percent occurrence.311,312
A detailed explanation of the mechanism of action of troman-
tadine has yet to be established. However, numerous studies
indicate that tromantadine inhibits both an early and a late stage
of viral replication.314 In early stages, it appears that it inhibits
the viral uncoating process. In later stages, it appears to inhibit
membrane fusion by changing host surface glycoproteins,
thereby interfering with absorption of the virus.313–315 This is
quite different from the mechanism of action of acyclovir (120),
which interferes with viral replication by inserting a nucleobase
analogue.316 Although tromantadine is not a first line treatment,
the different mechanisms of action mean that it may be appro-
priate in cases of acyclovir resistant HSV infections (Fig. 10).
Tromantadine was first synthesised by May and Peteri.308
However, Rosenthal improved the practical ease of this process
and increased the overall yield (Scheme 21).313 This involved
reacting amantadine (100) with chloroacetyl chloride, to give
N-(1-adamantyl)-2-chloroacetamide (121), which was then
reacted with the lithium anion of N,N-dimethylethanolamine
(122) to give tromantadine (119) in 72% yield (Scheme 21).
6.5. Vildagliptin and saxagliptin
Vildagliptin (123) and saxagliptin (124) are both orally active
antihyperglycemic agents used in the treatment of type II
diabetes.317–321 Saxagliptin was approved by the FDA, in 2009,
as a new molecular entity and marketed as Onglyzat (Bristol-
Meyer-Squibbs, AstraZeneca). It is approved for use in the EU
and Australia, where it is also used in combination with
metformin (125), sulfonylureas (126), thiazolidediones (127)
or insulin.322 It has been quite successful, ranking in the top
200 brand name US drugs in 2011 and 2012. In contrast,
vildagliptin has not been approved by the FDA, but has been
approved in the EU and Australia, where it is marketed as
Scheme 20 Synthesis of adapalene (111).
Fig. 10 Herpes simplex treatments tromantadine (119) and acyclovir (120).
Scheme 21 Synthesis of tromantadine (119).
Fig. 11 Pharmaceuticals used in the treatment of type II diabetes: vilda-
gliptin (123), saxagliptin (124), metformin (125), sulfonylureas (126) and
thiazolidinedione (127).
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Galvust (Novartis) and may be used in combination with
metformin, sulfonylureas or thiazolidediones (Fig. 11).323,324
Both drugs (i.e. 123 and 124) are potent and selective dipeptidyl
peptidase IV (DPP-IV) inhibitors. DPP-IV is a serine protease that
cleaves the N-terminal dipeptide from glucagon-like peptide 1
(GLP-1), and glucose-dependent insulinotropic peptide (GIP),
preventing their agonist activities at their GCPRs.325 GLP-1 stimu-
lates insulin production when blood glucose is high, suppresses
glucagon and lowers release of glucose by the liver.326 The rate of
food absorption is reduced, promoting satiety and lessening
appetite. Thus, GLP-1 is crucial to blood glucose homeostatsis
and inhibition of DPP-IV is an effective way to ensure that GLP-1
degradation is lessened.327
Vildagliptin and saxagliptin were both identified through
structure activity studies commencing from peptide derived
structures mimicking the DPP-IV substrate.317–321 Due to the
fact that they act as anti-hyperglycemics, the safety profiles of
both drugs are improved compared to hypoglycemics.327
Furthermore, they have been shown to be non-inferior to a
range of other treatments, and to be weight neutral.328–331
Animal studies suggest that vildagliptin may have relevance
for Alzheimer’s disease treatment.332,333
Hu et al. have reported the most efficient synthesis of
vildagliptin.334 L-Proline (128) was firstly reacted with chloro-
acetyl chloride to form 1-(2-chloroacetyl)-pyrrolidine-2-carboxylic
acid (129) (Scheme 22). This was reacted with 2,4,6-trichloro-
1,3,5-triazine (TCT) (130) affording 1-(2-chloroacetyl)-pyrrolidine-
2-carboxamide (131), which is then further dehydrated by
TCT producing 1-(2-chloroacetyl)-pyrrolidine-2-carbonitrile (132).
Reaction with 3-aminoadamantanol (133) yields vildagliptin (123)
(Scheme 22).
The saxagliptin synthesis was originally an approximate ten step
process.317 However, enzymatic syntheses utilising lipase B from
Candida antactica and dehydrogenase from Thermoactinomyces
intermedius, which provide better access to advanced intermediates,
have now been reported.335–337 Furthermore, an optimised com-
mercial scale synthesis, emphasising environmental and workplace
safety considerations, with five transformations, three isolations
and an overall yield of 65%, has been disclosed.338 Nevertheless,
the most illustrative synthesis is that initially described by Augeri
and Hamann.317 The synthesis firstly proceeded with conversion of
methyl adamantan-1-carboxylate (135) to the corresponding alde-
hyde (136). An asymmetric Strecker was then deployed, using
(R)-()-2-phenylglycinol with addition of potassium cyanide, which
delivered the advanced intermediate 137 that was subjected to
functional group manipulation giving the protected amino acid
138. Oxidation of the adamantane core with potassium permanga-
nate introduced the hydroxyl function (i.e. 139). Subsequent pep-
tide coupling with the commercially available cis-4,5-methano-
prolinamide (140) gave 141, which was finally followed by deprotec-
tion of the Boc protected amine, and dehydration of the primary
amide, to afford saxagliptin (124) (Scheme 23).
7. Polycyclic hydrocarbon analysis and
structural significance
In the DrugBank database alone over 1500 approved pharmaceu-
tical compounds are listed. It is, therefore, perhaps somewhatScheme 22 Synthesis of vildagliptin (123).
Scheme 23 Synthesis of saxagliptin (124).
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surprising that less than one percent of these compounds
incorporate all carbon polycyclic hydrocarbon scaffolds.
A cursory glance at the DrugBank database reveals the fact that
many drugs have relatively simple chemical structures, and
although many pharmaceuticals incorporate cyclic structures,
these motifs are often largely planar.11 It is our view that the
limited frequency of caged hydrocarbon scaffolds seen in the
clinic (Fig. 12) is largely attributable to aspects concerned with
(1) chemical synthesis, (2) the third dimension and complexity,
(3) natural products, and (4) target selection, ligand efficiency
and physicochemical properties.
7.1. Chemical synthesis encompassing polycyclic ring systems
In general, polycyclic hydrocarbon scaffolds usually command
significantly more synthetic challenges, due to difficulties in
functionalization. In addition, they often lack reaction and
functional group diversity as compared to aryl systems, and
have historically been of limited commercial supply as initial
building blocks. These factors have without doubt had a
negative impact on overall polycyclic structural diversity as
evidenced by the fact that only five polycyclic systems have
reached the clinic so far, i.e. bicyclo[2.2.1], [2.2.2], [4.4.1], [5.3.1]
and tricyclo[3.3.1.13,7] (adamantane) (Fig. 12).
That being said, the survey presented in Fig. 12 highlights
those structure classes that have maintained a high level
of popularity, such that viable synthesis have enabled their
drug discovery. Two examples that reinforce this notion is
the bicyclo[2.2.1] and adamantane systems. Utilising the
bicyclo[2.2.1] series (e.g. 5, 12, 16, 23, 30) (Fig. 12), as an initial
example, reveals a clear synthetic trend in the use of the robust
Diels–Alder reaction involving cyclopentadiene, which is readily
available and cheap. Of special note, however, is that all the
examples in this class that made it to the clinic (e.g. 5, 12, 16,
23, 30) have no substitution on two of the three bridges. This
lack of functionalisation is easily understood, because substi-
tuted cyclopentadienes invariably create regioisomers, via
the Diels–Alder reaction, which affect yield and thus cost (i.e.
potential requirement for chromatography). The adamantane
class (e.g. 100, 101, 111, 119, 124) highlights a similar situation,
in that, it is a popular structure class, but most are mono-
substituted, with only two examples being di-substituted (i.e.
123–124) (Fig. 12). This is a result of historical difficulties
associated with multi-functionalisation of the adamantane
system as compared to other motifs, although recent successful
efforts to overcome this issue (i.e. C–H functionalization) have
been reported.339
Fig. 12 A structural collection of the all-carbon polycyclic hydrocarbon scaffolds covered in this review.
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What about the many other bicyclo[1.x.x], [2.x.x], [3.x.x],
and so on, series of polycyclic systems missing from the clinic?
In fact, apart from natural products, only a few of the synthetic
systems (e.g. bicyclo[1.1.1],340 [3.2.1],341,342 [3.3.1]343,344) are
accompanied with any reasonable supporting synthetic literature.
These structure voids, however, have opened up many opportu-
nities for medicinal and synthetic chemists to develop new
systems and supporting reactions for functionalisation.
Wipf et al. have demonstrated that various amines (125)
containing the bicyclo[1.1.0] system can be prepared from
suitably protected imines and substituted bicyclo[1.1.0]lithium
anions (126) derived from tribrominated cyclopropanes (127)
(Scheme 24).345,346 Later, it was discovered that the bicyclo-
[1.1.0]amines (125) will undergo base promoted rearrangement
in the presence of various electrophiles to give fused bicyclo-
[2.1.1]pyrrolidines (128) (Scheme 24).345 An extensive biological
screening program evaluating the bicyclo[2.1.1]pyrrolidines (128)
unearthed a wide range of biological activities, including for
example, inhibition of the enzymes TGF-b and fatty acid synthase,
in addition to hepatitis C activity.345
A team at Pfizer lead by Stepan347 recently demonstrated
that bicyclo[1.1.1]pentane could act as a benzene function
replacement for the g-secretase inhibitor of BMS-708,163
(129) with the synthesis and biological evaluation of 130, which
demonstrated greater activity and drugability (Fig. 13). This,
however, was not the first example of benzene ring replacement
using the bicyclo[1.1.1]pentane system. In 1996 Pellicciari
reported348 that (S)-(+)-2-(30-carboxybicyclo[1.1.1]pentyl)glycine
(131) was a structurally novel, potent and selective, mGluR1
antagonist modeled off (+)-methyl(4-carboxyphenyl)glycine
(132), which was known to exhibit mGluR1 antagonist proper-
ties (Fig. 13). Lastly on this front, both these pieces of work
inspired Adsool et al.349 to prepare a benzene isostere of
4-phenylaniline (133) using the bicyclo[1.1.1]pentane scaffold
(i.e. 134) for an in-house drug discovery program.
Eaton, in the 1990s, suggested that the classical hydro-
carbon cubane (135) might also act as a benzene surrogate,
and went on to say this offers exciting prospects for pharma-
ceutical development.350 Although the known chemistry of cubane
is substantial,350,351 it is not at the same level of benzene substitu-
tion chemistry. Nevertheless, Wlochal and Davies352 have recently
demonstrated that incorporation of cubane into pharmaceutically
relevant containing molecules is possible (e.g. 136–138) (Fig. 14).
Furthermore, Schreiner recently synthesised aminocubane
(139) in addition to homo (140), bishomo (141) and trishomo
(142) cubane derivatives, and subsequently investigated their
bioactivity potential against NMDA receptors (Fig. 15). The
driving force for this study was the carbocyclic similarity of
the cubanes to memantine (105, see Section 6.2). Evaluation
of cubanes 139–142 in the hydrochloride form showed pro-
nounced affinity suggesting these systems would act as efficient
voltage-dependent NMDA receptor antagonists.353
7.2. The third dimension and complexity
Initiated by the advent of Lipinski’s rules354 the medicinal
chemistry community embarked on the adoption of substantial
computational analysis of screening libraries, hits, leads and
clinical drugs, to better understand attrition rates based on
physical properties (e.g. molecular weight, topological polar
Scheme 24 Synthesis of the bicyclo[1.1.0] and bicyclo[2.1.1] systems for
utilisation in bio-assay screening.
Fig. 13 Investigating the concept of bicyclo[1.1.1]pentane as a benzene
bioisostere.
Fig. 14 Cubane (135) and pharmaceutically relevant cubane derived
molecules (136–138).
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surface area, rotatable bonds, and hydrogen bond donors and
acceptors).355 However, the legacy of both combinatorial chem-
istry and the expansion of sp2 coupling and functionalization
methodologies, gave rise to a high proportion of aromatic
molecules within screening libraries, which therefore influenced
computational analyses towards the selection of planar sp2 rich
molecules eventuating in a ‘‘flatland’’ drug domination scenario.11
Flatland drugs,356 or perhaps more importantly flatland drug
candidate development programs, are raising real constraint
concerns in some quarters of the pharmaceutical drug design
and development community.357 Although total flatland with-
drawal would be counterproductive,358 avenues to sidestep
potential flat scaffold problems by the introduction of sp3
carbons has been proposed.11,356,359 Furthermore, increasing
overall saturation and thus ‘‘complexity’’,360 as indicated by
various measures (e.g. Fsp3),11,356,360 seems a viable path to
escape flatland. It also makes sense that deployment of chirality
and non-planar architecture construction will provide greater
access to new chemical space.361 Furthermore, chirality has
recently been proposed to address low-druggability recognition
sites,362 and complexity shown to potentially reduce toxicity,356
and increase target specificity.363 Surely, all these desirable
features could be justifiably addressed via the incorporation of a
polycyclic hydrocarbon system, which by their very nature are sp3
complex, often chiral and can potentially act as direct benzene
bioisosteres.
7.3. Natural products
There has been considerable debate in recent years about the
value and contribution of natural products to drug discovery
as evaluated by molecule types that reach the clinic.1–3,5
Evaluation of the 20 candidates discussed herein reveals a
conservative estimate that more than 50% are natural products,
or derivatives thereof. This is perhaps unsurprising when one
considers that adamantane is a natural product,248 and thus
the entire tricyclo[3.3.1.13,7] class, can then be considered as
naturally derived. Furthermore, the predominance of natural
products or derivative representatives is partially explained by
taking into account the fact that Mother Nature is able to
bypass many of the issues faced in attempting to synthesise
such bicyclic compounds. Thus, in the portion of drugs that are
natural products a high density of more structurally complex
compounds is not unexpected. Even in the extreme complexity
cases this did not impact on their development. For example, in
the case of both the taxanes (e.g. 1) and retapamulin (e.g. 84)
(see Section 5), not to mention buprenorphine (3) (see Section 3.2),
chemical synthesis was supplemented in part with readily available
bio-engineered advanced intermediates.364 Whereas, very recently
microbial synthesis potentially offers much promise to simplify
production of natural products from glucose.365
7.4. Target selection, ligand efficiency and physicochemical
properties
The 20 pharmaceuticals discussed in this review cover treatment
of a wide range of disorder types, conditions, and diseases (see
Fig. 12 overview). These include, (1) Parkinson’s treatments;
(2) antidiuretics to treat heart failure and hypertension; (3) anti-
hypertensives for hypertension and smoking cessation; (4) anti-
psychotics for appetite suppression, schizophrenia, and bipolar I
depression; (5) antidepressants; (6) analgesics for pain; (7) treat-
ment of actinic keratosis for skin cancer; (8) antineoplastic agents
for treating solid tumours; (9) antivirals, (10) antibacterials,
(11) acne treatments; and (12) hypoglycemics for the treatment
of diabetes.
So what is the key to understanding broad target diversity
and potency of polycyclic hydrocarbon drugs? Although the
aforementioned disorder types, conditions, and diseases are
wide-ranging, a common feature of the polycyclic hydrocarbon
class thus far is that many of these clinical agents engage
central nervous system (CNS) and/or neurological targets.
When the polycyclic cage is more exposed or predominates,
the majority of the molecule is inherently more lipophilic in
character (e.g. 5, 16, 30, 33, 73, 100) (Fig. 12). This confers on
such systems further attributes more suited to crossing the
blood brain barrier (BBB)366,367 and entering the CNS.368 That
being said, lipophilicity, which is not necessarily target depen-
dent, has a narrow window for optimal drug design (i.e. logD
1–3), but enviably correlates well with increased potency.369
Therefore, is lipophilicity the key desirably feature polycyclic
hydrocarbon scaffolds can provide? For those systems that have
the polycyclic hydrocarbon scaffold buried deep within the
drug (e.g. 1, 3, 44, 84) (Fig. 12), not only is a shift away from
CNS activity observed, but it is hard not to conceive that the
scaffold is key to rigid functional group placement. That is, the
attached functional groups are in high probability at the perfect
three-dimensional distances with in the binding pocket, which
impact substantially on ligand efficiency. Interestingly, ligand
efficiency metrics concentrate on both lipophilic ligand effi-
ciency and ligand binding thermodynamics and kinetics370
(i.e. entropy/enthalpy and Michaelis–Menten kinetics371). This
suggests that polycyclic hydrocarbon scaffolds could better
satisfy both criteria of lipophilicity and functional group placement
control, and thus limit undesirable polypharmacology372,373 or
metabolic profiles.252
8. Conclusion
It is clear that polycyclic hydrocarbon systems have played an
important role in the clinic thus far, however the meagre
impact of no greater than one percent compared to all other
clinical agents, is fuelling a welcomed renaissance in both
Fig. 15 Aminocubane (139), homo (140), bishomo (141) and trishomo
(142) cubane derivatives investigated for bioactivity potential against
NMDA receptors.
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traditional polycyclic hydrocarbon scaffolds and the development
of new medicinally relevant polycyclic hydrocarbon systems.
Furthermore, new developments in benzene bioisostere discovery,
anti-flatland complexity factors, and ligand efficiency measures
will drive research in this underdeveloped area. Lastly, it is our
view that the identification that limited classes of chemical reac-
tions are being deployed in the pharmaceutical sector374,375
together with the current search for new scaffolds376 will ultimately
reinforce caged polycyclic systems as a reliable medicinal chem-
istry scaffold having increased clinical impact well into the future.
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